HomeBusiness NewsTelix Pharmaceuticals Q1 2026: Revenue growth, guidance reaffirmed

Telix Pharmaceuticals Q1 2026: Revenue growth, guidance reaffirmed

April 7, 2026

- Advertisement -

The Telix Pharmaceuticals Ltd (ASX: TLX) share price is in focus after the company reported group revenue of US$230 million, up 11% quarter-over-quarter, and reaffirmed its FY 2026 revenue guidance.

Image source: Getty Images

What did Telix Pharmaceuticals report?

Unaudited group revenue of…

Click here to view the original article.

Tags
Fool.com.au

- Advertisment -

Farmers push for stronger protections in renewable energy benefit policy

Bradley Roberts-Smith arrested; WA fuel stocks improve; Petrol stations fined; Boy dies after scooter crash

Telix Pharmaceuticals Q1 2026: Revenue growth, guidance reaffirmed

What did Telix Pharmaceuticals report?

Recently Viewed

Households are about to be offered 3 hours of free power. Who should sign up, and who should think twice?

‘Tech firms are losing the public’: social media age bans near tipping point | Social media bans

Regional NETWORK 10 viewers get three month switch off reprieve

Jonathan Swan and Maggie Haberman’s Regime Change: The inside story of a presidency run on vanity, t…

FEATURED

Great White shark bites fishing boat off Sunshine Coast

Volcanic cloud from Whakaari White Island halts flights

Great Koala Count: Aussies urged to track sightings of iconic marsupials

POPULAR POSTS

AMP’s Diana Mousina and more join Finance Marketing Summit lineup

FIFA World Cup 2026 LIVE updates: France lead Sweden 2-0 as Mexico prepare for Ecuador; Norway edge past Ivory Coast 2-1

Mission to save NASA telescope that’s falling to Earth

POPULAR CATEGORY

FOLLOW US

Telix Pharmaceuticals Q1 2026: Revenue growth, guidance reaffirmed

What did Telix Pharmaceuticals report?

RELATED ARTICLES

Recently Viewed

FEATURED

POPULAR POSTS

POPULAR CATEGORY

FOLLOW US